High-cutoff Hemodialyzer to Reduce Chronic Inflammation in Hemodialysis Patients
Launched by MARTIN-LUTHER-UNIVERSITÄT HALLE-WITTENBERG · Sep 9, 2009
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
Patients with ESRD on chronic hemodialysis patients frequently have elevated markers of inflammation (e.g. serum CRP values). Hemodialysis may clear the blood from low molecular weight toxins and retention products such as creatinine, potassium, or urea. The dialyzer clearance of middle to high molecular weight substances such as cytokines and cytokine receptors is low. Nearly 50% of chronic dialysis patients have persistent subclinical inflammation which is strongly associated with cardiovascular disease and mortality. The study tests the hypothesis that removal of proteins in the weight r...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • regular hemodialysis for at least 3 months
- • treatment thrice weekly
- • high-flux hemodialyzer for at least 4 weeks
- • age \> 18 years and \< 80 years
- • at least one CRP value \> 5mg/L within 8 weeks before inclusion
- • able to understand and consent the study
- • written informed consent
- Exclusion Criteria:
- • no consent
- • clinically apparent acute infection
- • CRP \> 50 mg/L
- • serum albumin \< 3,5 mg/L
- • central venous line as dialysis access
- • immunosuppressive medication
- • pregnancy or lactation
- • inclusion into any other interventional trial
About Martin Luther Universität Halle Wittenberg
Martin-Luther-Universität Halle-Wittenberg (MLU) is a prestigious research institution located in Halle, Germany, renowned for its commitment to advancing scientific knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, MLU emphasizes rigorous research methodologies and ethical standards, fostering collaboration among interdisciplinary teams to address critical health challenges. The university's extensive network of researchers and clinicians enables the development and execution of high-quality clinical trials aimed at improving patient outcomes and contributing to the global body of medical research. Through its dedication to excellence, MLU plays a pivotal role in translating scientific discoveries into tangible healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Halle (Saale), Sachsen Anhalt, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials